{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:53:35Z","timestamp":1782989615316,"version":"3.54.5"},"reference-count":52,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: BCMA-targeted Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of Relapsed\/Refractory Multiple Myeloma (RRMM). However, the disease is not curable and progression after CAR T-cell treatment remains a challenge. Clonal hematopoiesis, specifically mutations in the DNA damage response gene PPM1D, has been linked to therapy resistance and inferior survival in lymphoma patients undergoing cellular therapy. The impact of PPM1D mutations on MM patient outcome after CAR T-cell therapy remains undefined. Methods: We conducted a retrospective single-center study of 83 patients with RRMM patients treated with idecabtagene vicleucel or ciltacabtagene autoleucel between 2022 and 2025. Next-generation sequencing was performed on peripheral blood mononuclear cells collected prior to CAR T-cell infusion to identify PPM1D exon 6 mutations (variant allele frequency &gt; 0.01). We analyzed associations between mutational status, clinical characteristics, toxicity, and survival. Results: PPM1D mutations were detected in 14.5% (12\/83) of patients. PPM1D-mutated patients had fewer prior autologous stem cell transplantation compared to wild-type patients (50% vs. 82%, p = 0.02) and presented more advanced disease burden and adverse prognostic features (R-ISS stage III 58% vs. 20%, p = 0.05). Notably, PPM1D status did not impact initial efficacy; complete remission rates were comparable between groups (67% vs. 69%). However, PPM1D mutations were significantly associated with inferior progression-free survival (PFS) (median PFS: 6 months vs. 16 months, p = 0.04). Regarding toxicity, the mutated subgroup exhibited significantly higher rates of grade \u22652 cytokine release syndrome and a trend toward increased neurotoxicity (25% vs. 7%). Conclusions: PPM1D clonal hematopoiesis is frequent in RRMM and despite deep initial responses, patients harboring PPM1D mutations face a significantly higher risk of early relapse. PPM1D mutations may serve as a biomarker for poor durability of response and should be further evaluated in larger, prospective trials.<\/jats:p>","DOI":"10.3390\/cancers18132032","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:11:49Z","timestamp":1782234709000},"page":"2032","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8959-5708","authenticated-orcid":false,"given":"Katharina","family":"van der Weg","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1736-812X","authenticated-orcid":false,"given":"Martina","family":"Bertschinger","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1323-3116","authenticated-orcid":false,"given":"Henning","family":"Nilius","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Inselspital, Bern University Hospital, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-1573","authenticated-orcid":false,"given":"Katja","family":"Seipel","sequence":"additional","affiliation":[{"name":"Department for Biomedical Research (DBMR), University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple Myeloma: Every Year a New Standard?","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved Survival in Multiple Myeloma and the Impact of Novel Therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple Myeloma: 2024 Update on Diagnosis, Risk-stratification, and Management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical Course of Patients With Relapsed Multiple Myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin. Proc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/s41375-024-02404-6","article-title":"LocoMMotion: A Study of Real-Life Current Standards of Care in Triple-Class Exposed Patients with Relapsed\/Refractory Multiple Myeloma\u20142-Year Follow-up (Final Analysis)","volume":"38","author":"Mateos","year":"2024","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody Therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current State and Next-Generation CAR-T Cells in Multiple Myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T Cell Therapy in Multiple Myeloma: Current Status and Future Challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-Cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sanoyan, D.A., Seipel, K., Bacher, U., Kronig, M.-N., Porret, N., Wiedemann, G., Daskalakis, M., and Pabst, T. (2023). Real-Life Experiences with CAR T-Cell Therapy with Idecabtagene Vicleucel (Ide-Cel) for Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma Patients. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10824-3"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-Cel vs Standard Regimens in Triple-Class\u2013Exposed Relapsed and Refractory Multiple Myeloma: Updated KarMMa-3 Analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-Term Remission and Survival in Patients with Relapsed or Refractory Multiple Myeloma after Treatment with LCAR-B38M CAR T Cells: 5-Year Follow-up of the LEGEND-2 Trial","volume":"17","author":"Xu","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-Cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Dhakal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/14712598.2024.2352591","article-title":"Cilta-Cel, a BCMA-Targeting CAR-T Therapy for Patients with Multiple Myeloma","volume":"24","author":"Jagannath","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e369897b","DOI":"10.1097\/01.HS9.0000967692.36989.7b","article-title":"S195: Idecabtagene Vicleucel (Ide-Cel) vs. Standard Regimens in Patients with Triple-Class\u2013Exposed (Tce) Relapsed and Refractory Multiple Myeloma (Rrmm): A Karmma-3 Analysis in High-Risk Subgroups","volume":"7","author":"Patel","year":"2023","journal-title":"HemaSphere"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T Cell Therapy: The Efficacy and Toxicity Balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","article-title":"Consensus Guidelines and Recommendations for the Management and Response Assessment of Chimeric Antigen Receptor T-Cell Therapy in Clinical Practice for Relapsed and Refractory Multiple Myeloma: A Report from the International Myeloma Working Group Immunotherapy Committee","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-Term (\u22655-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed\/Refractory Multiple Myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO-24-01730","article-title":"Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed\/Refractory Multiple Myeloma","volume":"43","author":"Hansen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and Clinical Efficacy of BCMA CAR-T-Cell Therapy in Multiple Myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer Therapy Shapes the Fitness Landscape of Clonal Hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1038\/s41467-022-31878-0","article-title":"Discovering the Drivers of Clonal Hematopoiesis","volume":"13","author":"Pich","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_28","first-page":"1599","article-title":"Clonal Hematopoiesis and Risk for Hematologic Malignancy","volume":"136","author":"Warren","year":"2020","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1073\/pnas.94.12.6048","article-title":"Wip1, a Novel Human Protein Phosphatase That Is Induced in Response to Ionizing Radiation in a P53-Dependent Manner","volume":"94","author":"Fiscella","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/bjh.17120","article-title":"Protein Phosphatase, Mg2+\/Mn2+-dependent 1D (PPM1D) Mutations in Haematological Cancer","volume":"192","author":"Husby","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10555-008-9127-x","article-title":"The Type 2C Phosphatase Wip1: An Oncogenic Regulator of Tumor Suppressor and DNA Damage Response Pathways","volume":"27","author":"Lu","year":"2008","journal-title":"Cancer Metastasis Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1101\/gad.1291305","article-title":"PPM1D Dephosphorylates Chk1 and P53 and Abrogates Cell Cycle Checkpoints","volume":"19","author":"Lu","year":"2005","journal-title":"Genes Dev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/emboj.2009.246","article-title":"Wip1 Confers G2 Checkpoint Recovery Competence by Counteracting P53-dependent Transcriptional Repression","volume":"28","author":"Lindqvist","year":"2009","journal-title":"EMBO J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"31563","DOI":"10.18632\/oncotarget.7325","article-title":"Wip1 Phosphatase: Between P53 and MAPK Kinases Pathways","volume":"7","author":"Goloudina","year":"2016","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1083\/jcb.201210031","article-title":"Gain-of-Function Mutations of PPM1D\/Wip1 Impair the P53-Dependent G1 Checkpoint","volume":"201","author":"Kleiblova","year":"2013","journal-title":"J. Cell Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1038\/s41388-024-03149-3","article-title":"PPM1D Activity Promotes Cellular Transformation by Preventing Senescence and Cell Death","volume":"43","author":"Stoyanov","year":"2024","journal-title":"Oncogene"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-Related Clonal Hematopoiesis in Patients with Non-Hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41467-018-02858-0","article-title":"Cellular Stressors Contribute to the Expansion of Hematopoietic Clones of Varying Leukemic Potential","volume":"9","author":"Wong","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2018-05-850339","article-title":"PPM1D-Truncating Mutations Confer Resistance to Chemotherapy and Sensitivity to PPM1D Inhibition in Hematopoietic Cells","volume":"132","author":"Kahn","year":"2018","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal Hematopoiesis in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal Hematopoiesis Is Associated with Adverse Outcomes in Multiple Myeloma Patients Undergoing Transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1097\/HS9.0000000000000957","article-title":"Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-Cell Treated Patients","volume":"7","author":"Panagiota","year":"2023","journal-title":"HemaSphere"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1038\/s41375-020-0795-z","article-title":"Clinical Impact of Clonal Hematopoiesis in Patients with Lymphoma Undergoing ASCT: A National Population-Based Cohort Study","volume":"34","author":"Husby","year":"2020","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Schmid, C.N., Sponagel, K., Bacher, U., Seipel, K., Porret, N., Wiedemann, G., Hoffmann, M., Daskalakis, M., and Pabst, T. (2025). Clonal Hematopoiesis and Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with AML, Myeloma, and Lymphoma. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26168021"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8197","DOI":"10.3390\/cimb46080484","article-title":"Rising Prevalence of Low-Frequency PPM1D Gene Mutations after Second HDCT in Multiple Myeloma","volume":"46","author":"Seipel","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"10463","DOI":"10.3390\/curroncol30120762","article-title":"Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma","volume":"30","author":"Seipel","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/therapeutics1020009","article-title":"Low-Frequency PPM1D Gene Mutations Associated with Inferior Treatment Response to CD19 Targeted CAR-T Cell Therapy in Mantle Cell Lymphoma","volume":"1","author":"Seipel","year":"2024","journal-title":"Therapeutics"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Therneau, T.M., and Grambsch, P.M. (2000). Modeling Survival Data: Extending the Cox Model, Springer. Statistics for Biology and Health.","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal Hematopoiesis Associated with TET2 Deficiency Accelerates Atherosclerosis Development in Mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCRESAHA.121.319314","article-title":"The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene Ppm1d Promotes Inflammation and Non-Ischemic Heart Failure in Mice","volume":"129","author":"Yura","year":"2021","journal-title":"Circ. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2032\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:32:03Z","timestamp":1782988323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":52,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132032"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132032","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}